Drug self-delivery systems for cancer therapy
Abstract
Carrier-assistant drug delivery systems (DDSs) have been rapidly established for cancer therapy and great strides have been made in recent years. However, further development of DDSs is retarded by the aspects such as the low drug carrying capacity, carrier-induced toxicity and immunogenicity, complex synthesis manipulation. Drug self-delivery systems (DSDSs), in which active drugs exhibit nanoscale characteristic to realize intracellular delivery by themselves without the help of nanocarriers, have been rapidly developed to address these issues. In this review, we present a comprehensive summary of the recent advances in DSDSs for cancer therapy. After a brief introduction to the major types of DSDSs and their fabrication strategies, we emphatically discuss some representative achievements of these DSDSs for passive or/and positive targeting therapy, combinational therapy as well as theranostics. The design principle is explained and justified, which can cast a new light on developing drug delivery systems for cancer treatments.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nanodrug delivery systems can deliver therapeutic agents precisely to the intended target.
“These nanocarriers possess the ability to deliver therapeutic agents precisely to the intended target.”
From Mussel-Inspired Injectable Adhesive Hydrogels for Biomedical Applications (2024) · cites this paper as [142]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 125 · Cited by 532
- Authors
- Qin, S.-Y., Zhang, A.-Q., Cheng, S.-X., Rong, L., & Zhang, X.-Z.
- Affiliations
- South Central Minzu University (CN)
- Wuhan University (CN)
- Corresponding author
- Zhang, Xian-Zheng
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 112
- Pages
- 234-247
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2530625287
- Cited by
- 532
- References
- 125
- Citations by year
- 2026: 12 · 2025: 34 · 2024: 56 · 2023: 53 · 2022: 62 · 2021: 72 · 2020: 75 · 2019: 69 · 2018: 65 · 2017: 32 · 2016: 2
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biomaterials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (51503227, 51233003, 51533006)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- cancer therapy, intracellular drug delivery, immunogenicity, passive targeting, active targeting, theranostics, drug delivery system design
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Design, Drug Delivery Systems, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review